NCT05350774View on ClinicalTrials.gov

Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 10, 2023

Primary Completion Date

December 15, 2025

Study Completion Date

December 15, 2025

Conditions
Systemic InflammationNeuroinflammationMicrovascular Thrombosis
Interventions
DRUG

IV normal saline

IV normal saline 250ml for 5 days

DRUG

IV immunoglobulin

IVIg - IV immunoglobulin 0.4g/kg/day for 5 days

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Neurological Disorders and Stroke (NINDS)

NIH